U.S. Liver Cancer Diagnostics Market Size & Outlook
U.S. liver cancer diagnostics market, 2018-2030 (US$M)
Related Markets
U.S. liver cancer diagnostics market highlights
- The U.S. liver cancer diagnostics market generated a revenue of USD 2,581.8 million in 2023 and is expected to reach USD 3,879.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6% from 2024 to 2030.
- In terms of segment, outpatient facilities was the largest revenue generating end use in 2023.
- Home Care is the most lucrative end use segment registering the fastest growth during the forecast period.
Liver cancer diagnostics market data book summary
| Market revenue in 2023 | USD 2,581.8 million |
| Market revenue in 2030 | USD 3,879.6 million |
| Growth rate | 6% (CAGR from 2023 to 2030) |
| Largest segment | Outpatient facilities |
| Fastest growing segment | Home Care |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
| Key market players worldwide | Abbott Laboratories, Thermo Fisher Scientific Inc, Roche Holding AG ADR, Qiagen NV, Siemens Healthineers AG ADR, Becton Dickinson & Co, Illumina Inc, Epigenomics AG, Koninklijke Philips NV, FUJIFILM Holdings Corp |
Other key industry trends
- In terms of revenue, U.S. accounted for 45.4% of the global liver cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. liver cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 3,879.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liver Cancer Diagnostics Market Scope
Liver Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. liver cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 58.87% in 2023. Horizon Databook has segmented the U.S. liver cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Growth in the number of initiatives undertaken by the government, various research activities conducted by research and academic institutes are some of the factors influencing the market growth in the near future. The American Cancer Society recommends screening for liver cancer with the AFP blood tests as well as ultrasound procedures every six months.
These tests are mostly recommended for individuals who are at a high risk of developing liver cancer as they have hereditary hemochromatosis, chronic hepatitis B infection, as well as cirrhosis. In addition, the Hepatitis Foundation also recommends regular screening of liver cancer in order to enhance treatment options and survival rates.
Reasons to subscribe to U.S. liver cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. liver cancer diagnostics market databook
-
Our clientele includes a mix of liver cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. liver cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. liver cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. liver cancer diagnostics market size, by end use, 2018-2030 (US$M)
U.S. Liver Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
